Quark Pharmaceuticals Announces First Patient Dosing By Pfizer In Phase II Trial Of RNAi Therapy In Diabetic Macular Edema
Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that its partner, Pfizer Inc, initiated patient dosing in a Phase II trial evaluating PF-4523655 (RTP801i-14) in patients with diabetic macular edema (DME). PF-4523655 is a novel siRNA drug candidate being co-developed by Quark and Pfizer.
Tags: age, macular, patientIf you enjoyed this post, please subscribe to the feed and get future articles delivered to your feed reader.